Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial

INTRODUCTION: Treatment resistant depression (TRD) is estimated to affect 10–30% of patients with major depressive disorder (Al‑Harbi et al. Patient Prefer Adherence 2012; 6 369–88). Esketamine nasal spray (NS), in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin norepin...

Descripción completa

Detalles Bibliográficos
Autores principales: Reif, A., Anıl Yağcıoğlu, A. E., Luts, A., Messer, T., Nielsen, R., Buyze, J., Ito, T., Kambarov, Y., Mulhern Haughey, S., Rive, B., Usankova, I., von Holt, C., Godinov, Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596645/
http://dx.doi.org/10.1192/j.eurpsy.2023.272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596645/
http://dx.doi.org/10.1192/j.eurpsy.2023.272

Ejemplares similares